Repare Therapeutics (RPTX) News Today $1.37 -0.07 (-4.86%) Closing price 07/3/2025 01:26 PM EasternExtended Trading$1.38 +0.01 (+0.66%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9% - Should You Sell?July 4 at 2:21 AM | marketbeat.comRepare Therapeutics Inc (RPTX) - Investing.comJuly 3 at 5:41 PM | investing.comRepare Therapeutics Inc (RPTX) Stock Forums - Investing.comJune 30, 2025 | investing.comRepare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic DealJune 25, 2025 | insidermonkey.comRepare Therapeutics Updates Severance Benefits for ExecutivesJune 20, 2025 | tipranks.comRepare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% - What's Next?June 7, 2025 | marketbeat.comRepare Therapeutics Strengthens Leadership with New Executive AppointmentJune 2, 2025 | tipranks.comMPM Asset Management LLC Has $2.21 Million Stock Position in Repare Therapeutics Inc. (NASDAQ:RPTX)May 16, 2025 | marketbeat.comMPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)May 16, 2025 | marketbeat.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comRepare Therapeutics Inc. Common Shares (RPTX)May 2, 2025 | nasdaq.comRepare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Down 20.4% in MarchApril 22, 2025 | marketbeat.comCathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare TherapeuticsApril 15, 2025 | investing.comRepare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeedsApril 1, 2025 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)April 1, 2025 | markets.businessinsider.comRepare Therapeutics Names Forte as President, CEOMarch 31, 2025 | marketwatch.comRepare Therapeutics Announces Leadership TransitionsMarch 31, 2025 | businesswire.comHC Wainwright Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $5.00March 8, 2025 | marketbeat.comRepare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | businesswire.comRepare Therapeutics price target lowered to $5 from $10 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comHere's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn SituationMarch 4, 2025 | uk.finance.yahoo.comRepare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 4, 2025 | finance.yahoo.comRepare Therapeutics reports Q4 EPS (67c), consensus (79c)March 3, 2025 | markets.businessinsider.comLifeSci Capital Sticks to Its Hold Rating for Repare Therapeutics (RPTX)March 3, 2025 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSMarch 3, 2025 | marketbeat.comRepare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | businesswire.comARK Investment Management LLC Cuts Stock Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX)February 27, 2025 | marketbeat.comLifeSci Capital Remains a Hold on Repare Therapeutics (RPTX)February 26, 2025 | markets.businessinsider.comCambridge-Montreal biotech lets go 75% of employeesFebruary 25, 2025 | bizjournals.comRepare Therapeutics (RPTX) Expected to Announce Quarterly Earnings on WednesdayFebruary 19, 2025 | marketbeat.comRepare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market ChallengesJanuary 23, 2025 | msn.comShort Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3%January 17, 2025 | marketbeat.comStrategic Shift and Uncertainties Lead to Hold Rating for Repare TherapeuticsJanuary 12, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Repare Therapeutics (RPTX)January 10, 2025 | markets.businessinsider.comRepare Therapeutics (RPTX) Gets a Hold from LifeSci CapitalJanuary 10, 2025 | markets.businessinsider.comRepare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost ReductionsJanuary 9, 2025 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX) and Centene (CNC)December 16, 2024 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Stock, Insider Trading ActivityDecember 14, 2024 | benzinga.comRepare Therapeutics (NASDAQ:RPTX) Stock, Short Interest ReportDecember 14, 2024 | benzinga.comRepare Therapeutics (NASDAQ:RPTX) Stock Quotes, Forecast and News SummaryDecember 14, 2024 | benzinga.comHold Rating on Repare Therapeutics Amid Mixed Trial Results and Anemia ConcernsDecember 14, 2024 | markets.businessinsider.comLifeSci Capital Downgrades Repare Therapeutics (RPTX)December 14, 2024 | msn.comRepare Therapeutics (NASDAQ:RPTX) Receives Market Perform Rating from Lifesci CapitalDecember 13, 2024 | marketbeat.comRepare Therapeutics Shares Drop 38% Following Phase 1 Trial ResultsDecember 13, 2024 | ca.finance.yahoo.comWhy Is Repare Therapeutics Stock Trading Lower On Friday?December 13, 2024 | uk.finance.yahoo.comWhy Is Repare Therapeutics Stock Trading Lower On Friday?December 13, 2024 | benzinga.comStifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00December 13, 2024 | marketbeat.comRepare Therapeutics reports ‘positive’ results from MYTHIC Phase 1 trialDecember 12, 2024 | markets.businessinsider.com Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address RPTX Media Mentions By Week RPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPTX News Sentiment▼0.000.54▲Average Medical News Sentiment RPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPTX Articles This Week▼32▲RPTX Articles Average Week Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aurora Cannabis News Neurogene News biote News Acelyrin News Semper Paratus Acquisition News Canopy Growth News ProQR Therapeutics News Nanobiotix News Y-mAbs Therapeutics News I-Mab News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPTX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
